Defeat GBM Research Collaborative
Our largest and boldest program to date, this strategic initiative aims to double the five-year survival rate of glioblastoma multiforme (GBM) patients in just five years, through robust research collaborations and a novel scientific construct. GBM is the deadliest form of brain cancer.
Clinical Trial Endpoints
This initiative works with the U.S. Food & Drug Administration (FDA) to recommend alternative (and additional) clinical trial endpoints to accelerate the pace of development for drugs, which will provide clinical benefits to patients.
Community Research Fund
The Community Research Fund allows contributors to pool donations to support research on a specific type of tumor. This program leverages a team of highly experienced, nationally-recognized scientific experts, working with the National Brain Tumor Society staff to determine the best investment strategy for each fund.
These programs seek to address the key barriers slowing pre-clinical research and investment in drug development, as well as identify treatment options which are safe and minimize long-term side effects on pediatric brain tumor patients.
We believe a systems biology-based research approach, focusing on the entire complex brain tumor system, can deliver more compelling insight and drive research to effective therapies much faster than under traditional research methods.
Advancing Research to Treatment (ART)
The program helps to translate laboratory science into commercialized brain tumor treatments by bringing together researchers, biotechnology and pharmaceutical executives, venture capital (VC) investors, and brain tumor patients to address the challenges surrounding drug development and patient access.
Within the world of research there are many leading organizations and experts, and we believe our collective contributions and scientific advancements will benefit the entire brain tumor community. As such, we empower researchers to bring new therapies to brain tumor patients through collaborations and partnerships with the National Brain Tumor Society.